Bioactivity | Blonanserin dihydrochloride is a potent and orally active 5-HT2A and dopamine D2 receptor antagonist, with Ki values of 0.812 and 0.142 nM, respectively. Blonanserin dihydrochloride is usually acts as an atypical antipsychotic agent, and can be used for the research of extrapyramidal symptoms, excessive sedation, or hypotension[1][2]. |
Invitro | Blonanserin dihydrochloride exerts some blockade of α1-adrenergic receptors (Ki=26.7 nM) and also shows significant affinity for the D3 receptor (Ki=0.494 nM). Blonanserin dihydrochloride possesses low affinity for the sigma receptor (IC50=286 nM), but lacks significant affinity for numerous other sites including the 5-HT1A, 5-HT3, D1, α2-adrenergic, β-adrenergic, H1, and mACh receptors and the monoamine transporters[1]. |
In Vivo | Blonanserin dihydrochloride (Oral gavage; 1 mg/kg; once a day for 14 days) significantly ameliorates the social deficit observed in PCP-administered mice and inhibits the decrease in the levels of Ser897-phosphorylation, but preatment with blonanserin does not affect the social behaviors in saline-administered mice[2]. Animal Model: |
Name | Blonanserin dihydrochloride |
CAS | 132812-45-4 |
Formula | C23H32Cl2FN3 |
Molar Mass | 440.42 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Blonanserin [2]. Saori Takeuchi, et al. Blonanserin ameliorates social deficit through dopamine-D 3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia. Neurochem Int. 2019 Sep;128:127-134. |